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June 20121834 Abstractsature on intra-abdominal reversible adverse outcomes and permanent ad-
verse outcomes after DTA and TAAA open repair. This was a retrospective
review of patients at the authors’ institution who underwent open DTA and
TAAA repair between January 2002 and December 2008. The authors
included relevant preoperative, intraoperative, and postoperative data and
performed a propensity score-matched analysis. Data sufficient to permit
analysis were available for 240 of 262 patients, with 90 suitable for the
propensity-matched study. Reversible adverse outcomes included analysis
for renal failure, temporary hemodialysis, and liver failure. Permanent ad-
verse outcomes identified were permanent hemodialysis, 30-day mortality,
and paraplegia. The 30-day mortality was 7.1% (17 of 240). Reversible
adverse outcomes developed in 40.8% of patients and permanent adverse
outcomes in 10%. Propensity score analysis identified decreased odds of
developing reversible adverse outcomes in patients undergoing DHCA
(odds ratio, 0.32: 95% confidence interval, 0.12-0.85). Rates of acute renal
failure (22% vs 46.4%, P  .03) and liver failure (17.8% vs 34.3%, P  .04)
were lower in patients who underwent DHCA compared with the non-
DHCA group.
Comment:Regionalization of complex procedures makes sense, and in
vascular surgery, open thoracoabdominal surgery should be regionalized.
Patients may not like to travel for care, but they do not want to die or
become paralyzed as a result of their care either. Only a small minority of
hospitals have the patient volume, technical expertise, and institutional
resources to really do open TAAA surgery well. That number will be even
smaller for those using DHCA to facilitate TAAA surgery. If DHCA is truly
a useful adjunct in TAAA surgery, it is still another reason to argue for
regionalization of TAAA surgery.
Combination Oral Antiplatelet Therapy may Increase the Risk of
Hemorrhagic Complications in Patients With Acute Ischemic Stroke
Caused by Large Artery Disease
Itabashi R, Mori E, Furui E, et al. Thromb Res 2011;128:541-6.
Conclusion: The incidence of hemorrhagic complications is likely
increased in patients with acute ischemic stroke secondary to large artery
disease who are treated with combination antiplatelet therapy.
Summary: It is recommended oral antiplatelet therapy be administered
immediately after acute ischemic stroke to prevent recurrence and progres-
sion of stroke as well as to prevent other vascular events. It is known that
monotherapy with aspirin does not reduce stroke progression (MarkusHS et
al, Circulation 2005;111:2233-40). However, it is thought that combina-
tion antiplatelet therapy, such as that provided by clopidogrel and aspirin,
may have a role in reducing stroke progression in patients with stroke
secondary to large artery disease (Wong KS et al, Lancet Neurol 2010;9:
489-97; Diener HC et al, Lancet 2004;64:331-7). There is an increased risk
of hemorrhagic complications with long-term secondary preventative ther-
apy with combination antiplatelet agents (Bhatt DL et al, N Engl J Med
2006;354:1706-17; Gasparyan AY et. al, J Am Coll Cardiol 2008;5:1829-
43). The risk of combination antiplatelet therapy in the short-term treat-
ment of acute stroke is not well understood. This retrospective study
evaluated bleeding complications associated with antiplatelet therapy in
patients with ischemic stroke secondary to large artery disease who were felt
to be at high risk for stroke recurrence or progression. The authors reviewed
1335 consecutive patients admitted 7 days of an ischemic stroke or
transient ischemic attack between April 2005 and November 2009. There
were 167 patients with 50% stenosis or occlusion of a culprit major vessel
treated with antiplatelet agents 48 hours of admission. Hemorrhagic
complications were classified according to the bleeding severity index. Of the
167 patients studied, 108 were treated with combination antiplatelet agents
and 59 with one antiplatelet agent. Three major and 11 minor hemorrhagic
complications occurred in 14 patients. All major hemorrhagic complications
occurred in patients administered combination antiplatelet therapy. The
proportion of patients receiving combination agents was higher in those
with significant hemorrhagic complications. Older age and receiving com-
bination antiplatelet agents were independent predictors of a significant
in-hospital hemorrhagic complication.
Comment: Despite the retrospective study design and the small num-
ber of end points, this study raises questions about the overall safety of
combination antiplatelet therapy in the treatment of ischemic stroke caused
by large artery disease. It is important to keep inmind that antiplatelet agents
work through different mechanisms of action. It is therefore not surprising
that the untoward effects of the sum may be greater than that observed with
individual agents. This study will help determine appropriate statistical
power for larger more definitive clinical trials with respect to end points and
safety monitoring.
Defining Perioperative Mortality after Open and Endovascular Aortic
Aneurysm Repair in the US Medicare Population
Schermerhorn ML, Giles KA, Sachs T, et al. J Am Coll Surg 2011;212:349-
55.
o
iConclusions: Comparisons of in-hospital mortality overestimate the
enefit of endovascular abdominal aortic aneurysm (AAA) repair (EVAR)
ompared with 30-day or combined 30-day and in-hospital mortality. The
uration of highest mortality risk extends longer for open repair, and the
otal mortality impact of AAA repair is not realized until 3 months after
epair.
Summary: Perioperative mortality is an important measure of quality
or surgical procedures. Definitions of the “perioperative” period differ.
erioperative mortality may be defined as death during the initial hospital-
zation, 30 days of surgery, or all deaths 30 days plus any deaths 30
ays that occur before hospital discharge. In addition, ongoing risks due to
urgery may persist 30 days and beyond hospital discharge. The authors
nvestigated the affects and implications of various methods of calculating
perioperative mortality” with respect to EVAR vs open AAA repair. They
sed propensity-scoring models to create matched cohorts of U.S. Medicare
eneficiaries undergoing EVAR (n  22,830) or open repair (n  22,830)
rom 2001 to 2004. Perioperative mortality was calculated using in-hospital
ortality, 30-day mortality, and combined 30-day and in-hospital mortality.
he authors also calculated biweekly interval death rates for 12 months to
efine the duration of increased risk for death after AAA repair. In-hospital,
0-day, and combined 30-day and in-hospital mortality for open repair and
VAR were 4.6% vs 1.1%, 4.8% vs 1.6%, and 5.3% vs 1.7%, respectively.
bsolute differences in mortality were similar at 3.5%, 3.2%, and 3.7%.
elative rates of death (95% confidence interval) were 4.2 (3.6-4.8), 3.1
2.7-3.4), and 3.2 (2.8-3.5). Biweekly interval death rates were highest
uring the first month after EVAR (0.6%) and during the first 2.5 months
0.5% to 2.1%) after open repair. After 2.5 months, rates were similar for
oth repairs (0.5%) and were stabilized after 3 months. The 90-day
ortality rates were 7.0% for open repair and 3.2% for EVAR.
Comment: The main point here is not that AAA patients undergoing
VAR or open repair continue to experience procedure-related morbidity
eyond their hospital stay or the first 30 postoperative days. We all have seen
ate procedure-related complications in our patients. However, it seems we,
s surgeons, by focusing on 30-day and/or in-hospital morbidity and
ortality, underestimate in the surgical literature the effect of our proce-
ures on our patients. Perhaps, for procedures of greater magnitude, such as
AA repair, journal editors should encourage reporting of periprocedural
orbidity and mortality data out to 3 months.
icroembolization During Carotid Artery Stenting in Patients With
igh-Risk, Lipid-Rich Plaque: A Randomized Trial of Proximal Vs
istal Cerebral Protection
ontorsi P, Caputi L, Galli S, et al. J Am Coll Cardiol 2011;58:1656-63.
Conclusion: In patients undergoing carotid artery stenting (CAS) who
ave a lipid-rich plaque, the use of a proximal cerebral protection system
uring CAS results in lower numbers of microemboli compared with distal
erebral protection with a filter wire during CAS.
Summary: It is well recognized distal cerebral protection during CAS
oes not fully prevent embolic complications. The reasons for this are
nclear but may include unprotected crossing of the lesion, incomplete
pposition of the device to the arterial wall, emboli smaller than the filter
ore size, and loss of debris with filter recapture. Proximal endovascular
cclusion using balloons to occlude the external carotid artery and the
ommon carotid artery, resulting in blood flow arrest in the internal carotid
rtery during CAS, may be a better technique for providing cerebral protec-
ion. Although the proximal occlusion technique has several potential draw-
acks, including patient intolerance to occlusion, potential dissection of the
xternal carotid artery, and need for a larger sheath (8F/9F), the potential to
ecrease microembolic events during CAS is intriguing. Increased numbers
f microembolic signals (MES) detected with transcranial Doppler (TCD)
ave been associated with a greater prevalence of silent ischemic cerebral
esions detected on post-CAS magnetic resonance diffusion-weighted imag-
ng (DWI). The significance of silent DWI-detected ischemic lesions after
arotid intervention is unknown, but there is some suggestion they could be
ssociated with late cognitive decline. Patients with lipid-rich plaque appear
lso to be at higher risk because they have an increased prevalence of
WI-detected lesions after CAS. The authors studied 53 consecutive pa-
ients with lipid-rich plaque undergoing CAS who were randomized to a
roximal protection device (n  26) or distal protection (n  27) with a
lter wire. MES were assessed with TCD during crossing of the lesion,
efore dilation, stent crossing, stent deployment, stent dilation, and during
evice retrieval/deflation. DWI was performed before CAS and after CAS at
8 hours and 30 days. Patients treated with the proximal cerebral protection
evice had a higher rate of ulcerated plaque than those whose cerebral
rotection was provided with a filter wire (35% vs 7.4%; P  .019).
ompared with the filter wire, the proximal cerebral protection device
educed the mean number of TCD-detected MES during crossing of the
esion (18 vs 2, P .001), stent crossing (23 vs 0), stent deployment (30 vs
), stent dilation (16 vs 0), and the total number of MES detected (93 vs
6). Multivariable analysis showed the type of cerebral protection was the
nly independent predictor of totalMES. There was no significant difference
n the number of patients with new post-CAS embolic lesions in the
